Todd Fox

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

P.C.M. van de Kerkhof, C.E.M. Griffiths, Kristian Reich et al. · Journal of the American Academy of Dermatology · 2016 · 304 citations

Medicine, Dermatology, Immunology +13

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan et al. · Annals of the Rheumatic Diseases · 2019 · 195 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections

Michael Kammüller, Tsen‐Fang Tsai, C.E.M. Griffiths et al. · Clinical & Translational Immunology · 2017 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

Boni E. Elewski, L. Puig, Margaret Mordin et al. · Journal of Dermatological Treatment · 2017 · 57 citations

Medicine, Dermatology, Pharmacotherapy +13

TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis

Ainhoa Arbués, Dominique Brees, Salah‐Dine Chibout et al. · PLoS Pathogens · 2020 · 53 citations · Full text

Life Sciences, Immunology, Pharmacology +17